Cortecs International Ltd. regulatory update

DLVRY filed an NDA with the FDA for its formulation of oral salmon calcitonin to treat osteoporosis. Salmon calcitonin, which inhibits the process of bone breakdown, is available in the U.S. to treat the disease in subcutaneous and intranasal formulations. ...